English
简体中文
Total: £ 56.28
Published Date: 2025-10-08 | Pages: 142 | Tables: 140 | Medical Care
The global Peptide-Drug Conjugates(PDCs) CDMO Service market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Peptide-drug conjugates (PDCs) consist of a cytotoxic payload, a homing peptide, and a linker between the peptide and the cytotoxic payload. Following antibody-drug conjugates, they are the next generation of targeted therapeutics with enhanced cell permeability and better drug selectivity. They offer excellent opportunities for targeting cancer, metabolic diseases, and more. Although the potential is huge, development challenges such as poor stability, poor targeting, and potential payload toxicity may slow down preclinical and clinical development processes. CDMO services refer to pharmaceutical companies and biotechnology companies outsourcing the research and development and production of their drugs or biologics to professional CDMO companies. These CDMO companies provide a range of services, including but not limited to drug synthesis, chemical and biological analysis, formulation development, clinical production, and commercial production. The core of CDMO services lies in its customization and specialization capabilities, which can meet the specific needs of different customers at different stages.
From a downstream perspective, SME Pharmaceutical Company accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Peptide-Drug Conjugates(PDCs) CDMO Service leading manufacturers including WUXIAPP, Medicilon, Creative Peptides, Peptistar, BOCSCI Inc, HUATENG PHARMA, CPC Scientific Inc, Porton, VIVA Biotech, Taichu Group, etc., dominate supply; the top five capture approximately % of global revenue, with WUXIAPP leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Peptide-Drug Conjugates(PDCs) CDMO Service market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
WUXIAPP
Medicilon
Creative Peptides
Peptistar
BOCSCI Inc
HUATENG PHARMA
CPC Scientific Inc
Porton
VIVA Biotech
Taichu Group
PharosGen
CENTER LABORATORIES, INC
JIUZHOU Pharmaceutical
Segment by Type
Therapeutic
Diagnostic
Segment by Application
SME Pharmaceutical Company
Large Pharmaceutical Company
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Peptide-Drug Conjugates(PDCs) CDMO Service study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Peptide-Drug Conjugates(PDCs) CDMO Service: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Therapeutic
1.2.3 Diagnostic
1.3 Market Segmentation by Application
1.3.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 SME Pharmaceutical Company
1.3.3 Large Pharmaceutical Company
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Estimates and Forecasts 2020-2031
2.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Therapeutic Market Size by Players
3.3.2 Diagnostic Market Size by Players
3.4 Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2020-2031)
6.4 North America Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2020-2031)
7.4 Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2020-2031)
8.4 Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2020-2031)
9.4 Central and South America Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2020-2031)
10.4 Middle East and Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 WUXIAPP
11.1.1 WUXIAPP Corporation Information
11.1.2 WUXIAPP Business Overview
11.1.3 WUXIAPP Peptide-Drug Conjugates(PDCs) CDMO Service Product Features and Attributes
11.1.4 WUXIAPP Peptide-Drug Conjugates(PDCs) CDMO Service Revenue and Gross Margin (2020-2025)
11.1.5 WUXIAPP Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Product in 2024
11.1.6 WUXIAPP Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Application in 2024
11.1.7 WUXIAPP Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Geographic Area in 2024
11.1.8 WUXIAPP Peptide-Drug Conjugates(PDCs) CDMO Service SWOT Analysis
11.1.9 WUXIAPP Recent Developments
11.2 Medicilon
11.2.1 Medicilon Corporation Information
11.2.2 Medicilon Business Overview
11.2.3 Medicilon Peptide-Drug Conjugates(PDCs) CDMO Service Product Features and Attributes
11.2.4 Medicilon Peptide-Drug Conjugates(PDCs) CDMO Service Revenue and Gross Margin (2020-2025)
11.2.5 Medicilon Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Product in 2024
11.2.6 Medicilon Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Application in 2024
11.2.7 Medicilon Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Geographic Area in 2024
11.2.8 Medicilon Peptide-Drug Conjugates(PDCs) CDMO Service SWOT Analysis
11.2.9 Medicilon Recent Developments
11.3 Creative Peptides
11.3.1 Creative Peptides Corporation Information
11.3.2 Creative Peptides Business Overview
11.3.3 Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Product Features and Attributes
11.3.4 Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Revenue and Gross Margin (2020-2025)
11.3.5 Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Product in 2024
11.3.6 Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Application in 2024
11.3.7 Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Geographic Area in 2024
11.3.8 Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service SWOT Analysis
11.3.9 Creative Peptides Recent Developments
11.4 Peptistar
11.4.1 Peptistar Corporation Information
11.4.2 Peptistar Business Overview
11.4.3 Peptistar Peptide-Drug Conjugates(PDCs) CDMO Service Product Features and Attributes
11.4.4 Peptistar Peptide-Drug Conjugates(PDCs) CDMO Service Revenue and Gross Margin (2020-2025)
11.4.5 Peptistar Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Product in 2024
11.4.6 Peptistar Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Application in 2024
11.4.7 Peptistar Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Geographic Area in 2024
11.4.8 Peptistar Peptide-Drug Conjugates(PDCs) CDMO Service SWOT Analysis
11.4.9 Peptistar Recent Developments
11.5 BOCSCI Inc
11.5.1 BOCSCI Inc Corporation Information
11.5.2 BOCSCI Inc Business Overview
11.5.3 BOCSCI Inc Peptide-Drug Conjugates(PDCs) CDMO Service Product Features and Attributes
11.5.4 BOCSCI Inc Peptide-Drug Conjugates(PDCs) CDMO Service Revenue and Gross Margin (2020-2025)
11.5.5 BOCSCI Inc Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Product in 2024
11.5.6 BOCSCI Inc Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Application in 2024
11.5.7 BOCSCI Inc Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Geographic Area in 2024
11.5.8 BOCSCI Inc Peptide-Drug Conjugates(PDCs) CDMO Service SWOT Analysis
11.5.9 BOCSCI Inc Recent Developments
11.6 HUATENG PHARMA
11.6.1 HUATENG PHARMA Corporation Information
11.6.2 HUATENG PHARMA Business Overview
11.6.3 HUATENG PHARMA Peptide-Drug Conjugates(PDCs) CDMO Service Product Features and Attributes
11.6.4 HUATENG PHARMA Peptide-Drug Conjugates(PDCs) CDMO Service Revenue and Gross Margin (2020-2025)
11.6.5 HUATENG PHARMA Recent Developments
11.7 CPC Scientific Inc
11.7.1 CPC Scientific Inc Corporation Information
11.7.2 CPC Scientific Inc Business Overview
11.7.3 CPC Scientific Inc Peptide-Drug Conjugates(PDCs) CDMO Service Product Features and Attributes
11.7.4 CPC Scientific Inc Peptide-Drug Conjugates(PDCs) CDMO Service Revenue and Gross Margin (2020-2025)
11.7.5 CPC Scientific Inc Recent Developments
11.8 Porton
11.8.1 Porton Corporation Information
11.8.2 Porton Business Overview
11.8.3 Porton Peptide-Drug Conjugates(PDCs) CDMO Service Product Features and Attributes
11.8.4 Porton Peptide-Drug Conjugates(PDCs) CDMO Service Revenue and Gross Margin (2020-2025)
11.8.5 Porton Recent Developments
11.9 VIVA Biotech
11.9.1 VIVA Biotech Corporation Information
11.9.2 VIVA Biotech Business Overview
11.9.3 VIVA Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Product Features and Attributes
11.9.4 VIVA Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Revenue and Gross Margin (2020-2025)
11.9.5 VIVA Biotech Recent Developments
11.10 Taichu Group
11.10.1 Taichu Group Corporation Information
11.10.2 Taichu Group Business Overview
11.10.3 Taichu Group Peptide-Drug Conjugates(PDCs) CDMO Service Product Features and Attributes
11.10.4 Taichu Group Peptide-Drug Conjugates(PDCs) CDMO Service Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 PharosGen
11.11.1 PharosGen Corporation Information
11.11.2 PharosGen Business Overview
11.11.3 PharosGen Peptide-Drug Conjugates(PDCs) CDMO Service Product Features and Attributes
11.11.4 PharosGen Peptide-Drug Conjugates(PDCs) CDMO Service Revenue and Gross Margin (2020-2025)
11.11.5 PharosGen Recent Developments
11.12 CENTER LABORATORIES, INC
11.12.1 CENTER LABORATORIES, INC Corporation Information
11.12.2 CENTER LABORATORIES, INC Business Overview
11.12.3 CENTER LABORATORIES, INC Peptide-Drug Conjugates(PDCs) CDMO Service Product Features and Attributes
11.12.4 CENTER LABORATORIES, INC Peptide-Drug Conjugates(PDCs) CDMO Service Revenue and Gross Margin (2020-2025)
11.12.5 CENTER LABORATORIES, INC Recent Developments
11.13 JIUZHOU Pharmaceutical
11.13.1 JIUZHOU Pharmaceutical Corporation Information
11.13.2 JIUZHOU Pharmaceutical Business Overview
11.13.3 JIUZHOU Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Product Features and Attributes
11.13.4 JIUZHOU Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Revenue and Gross Margin (2020-2025)
11.13.5 JIUZHOU Pharmaceutical Recent Developments
12 Peptide-Drug Conjugates(PDCs) CDMO ServiceIndustry Chain Analysis
12.1 Peptide-Drug Conjugates(PDCs) CDMO Service Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Peptide-Drug Conjugates(PDCs) CDMO Service Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Peptide-Drug Conjugates(PDCs) CDMO Service Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Peptide-Drug Conjugates(PDCs) CDMO Service by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide-Drug Conjugates(PDCs) CDMO Service as of 2024)
Table 11. Global Peptide-Drug Conjugates(PDCs) CDMO Service Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Peptide-Drug Conjugates(PDCs) CDMO Service Companies Headquarters
Table 13. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Application (2026-2031) & (US$ Million)
Table 21. Peptide-Drug Conjugates(PDCs) CDMO Service High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Peptide-Drug Conjugates(PDCs) CDMO Service Growth Accelerators and Market Barriers
Table 25. North America Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Growth Accelerators and Market Barriers
Table 27. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Peptide-Drug Conjugates(PDCs) CDMO Service Investment Opportunities and Key Challenges
Table 31. Central and South America Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Peptide-Drug Conjugates(PDCs) CDMO Service Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. WUXIAPP Corporation Information
Table 35. WUXIAPP Description and Major Businesses
Table 36. WUXIAPP Product Features and Attributes
Table 37. WUXIAPP Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. WUXIAPP Revenue Proportion by Product in 2024
Table 39. WUXIAPP Revenue Proportion by Application in 2024
Table 40. WUXIAPP Revenue Proportion by Geographic Area in 2024
Table 41. WUXIAPP Peptide-Drug Conjugates(PDCs) CDMO Service SWOT Analysis
Table 42. WUXIAPP Recent Developments
Table 43. Medicilon Corporation Information
Table 44. Medicilon Description and Major Businesses
Table 45. Medicilon Product Features and Attributes
Table 46. Medicilon Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Medicilon Revenue Proportion by Product in 2024
Table 48. Medicilon Revenue Proportion by Application in 2024
Table 49. Medicilon Revenue Proportion by Geographic Area in 2024
Table 50. Medicilon Peptide-Drug Conjugates(PDCs) CDMO Service SWOT Analysis
Table 51. Medicilon Recent Developments
Table 52. Creative Peptides Corporation Information
Table 53. Creative Peptides Description and Major Businesses
Table 54. Creative Peptides Product Features and Attributes
Table 55. Creative Peptides Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Creative Peptides Revenue Proportion by Product in 2024
Table 57. Creative Peptides Revenue Proportion by Application in 2024
Table 58. Creative Peptides Revenue Proportion by Geographic Area in 2024
Table 59. Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service SWOT Analysis
Table 60. Creative Peptides Recent Developments
Table 61. Peptistar Corporation Information
Table 62. Peptistar Description and Major Businesses
Table 63. Peptistar Product Features and Attributes
Table 64. Peptistar Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Peptistar Revenue Proportion by Product in 2024
Table 66. Peptistar Revenue Proportion by Application in 2024
Table 67. Peptistar Revenue Proportion by Geographic Area in 2024
Table 68. Peptistar Peptide-Drug Conjugates(PDCs) CDMO Service SWOT Analysis
Table 69. Peptistar Recent Developments
Table 70. BOCSCI Inc Corporation Information
Table 71. BOCSCI Inc Description and Major Businesses
Table 72. BOCSCI Inc Product Features and Attributes
Table 73. BOCSCI Inc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. BOCSCI Inc Revenue Proportion by Product in 2024
Table 75. BOCSCI Inc Revenue Proportion by Application in 2024
Table 76. BOCSCI Inc Revenue Proportion by Geographic Area in 2024
Table 77. BOCSCI Inc Peptide-Drug Conjugates(PDCs) CDMO Service SWOT Analysis
Table 78. BOCSCI Inc Recent Developments
Table 79. HUATENG PHARMA Corporation Information
Table 80. HUATENG PHARMA Description and Major Businesses
Table 81. HUATENG PHARMA Product Features and Attributes
Table 82. HUATENG PHARMA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. HUATENG PHARMA Recent Developments
Table 84. CPC Scientific Inc Corporation Information
Table 85. CPC Scientific Inc Description and Major Businesses
Table 86. CPC Scientific Inc Product Features and Attributes
Table 87. CPC Scientific Inc Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. CPC Scientific Inc Recent Developments
Table 89. Porton Corporation Information
Table 90. Porton Description and Major Businesses
Table 91. Porton Product Features and Attributes
Table 92. Porton Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Porton Recent Developments
Table 94. VIVA Biotech Corporation Information
Table 95. VIVA Biotech Description and Major Businesses
Table 96. VIVA Biotech Product Features and Attributes
Table 97. VIVA Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. VIVA Biotech Recent Developments
Table 99. Taichu Group Corporation Information
Table 100. Taichu Group Description and Major Businesses
Table 101. Taichu Group Product Features and Attributes
Table 102. Taichu Group Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Taichu Group Recent Developments
Table 104. PharosGen Corporation Information
Table 105. PharosGen Description and Major Businesses
Table 106. PharosGen Product Features and Attributes
Table 107. PharosGen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. PharosGen Recent Developments
Table 109. CENTER LABORATORIES, INC Corporation Information
Table 110. CENTER LABORATORIES, INC Description and Major Businesses
Table 111. CENTER LABORATORIES, INC Product Features and Attributes
Table 112. CENTER LABORATORIES, INC Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. CENTER LABORATORIES, INC Recent Developments
Table 114. JIUZHOU Pharmaceutical Corporation Information
Table 115. JIUZHOU Pharmaceutical Description and Major Businesses
Table 116. JIUZHOU Pharmaceutical Product Features and Attributes
Table 117. JIUZHOU Pharmaceutical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. JIUZHOU Pharmaceutical Recent Developments
Table 119. Raw Materials Key Suppliers
Table 120. Distributors List
Table 121. Market Trends and Market Evolution
Table 122. Market Drivers and Opportunities
Table 123. Market Challenges, Risks, and Restraints
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Peptide-Drug Conjugates(PDCs) CDMO Service Product Picture
Figure 2. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Therapeutic Product Picture
Figure 4. Diagnostic Product Picture
Figure 5. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. SME Pharmaceutical Company
Figure 7. Large Pharmaceutical Company
Figure 8. Peptide-Drug Conjugates(PDCs) CDMO Service Report Years Considered
Figure 9. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 10. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 11. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 12. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share by Region (2020-2031)
Figure 13. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share Ranking (2024)
Figure 14. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 15. Therapeutic Revenue Market Share by Player in 2024
Figure 16. Diagnostic Revenue Market Share by Player in 2024
Figure 17. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share by Type (2020-2031)
Figure 18. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share by Application (2020-2031)
Figure 19. North America Peptide-Drug Conjugates(PDCs) CDMO Service Revenue YoY (2020-2031) & (US$ Million)
Figure 20. North America Top 5 Players Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (US$ Million) in 2024
Figure 21. North America Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (US$ Million) by Type (2020 - 2031)
Figure 22. North America Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (US$ Million) by Application (2020-2031)
Figure 23. US Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 24. Canada Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 25. Mexico Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 26. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Revenue YoY (2020-2031) & (US$ Million)
Figure 27. Europe Top 5 Players Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (US$ Million) in 2024
Figure 28. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (US$ Million) by Type (2020-2031)
Figure 29. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (US$ Million) by Application (2020-2031)
Figure 30. Germany Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 31. France Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 32. U.K. Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 33. Italy Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 34. Russia Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Revenue YoY (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Top 8 Players Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (US$ Million) in 2024
Figure 37. Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (US$ Million) by Type (2020-2031)
Figure 38. Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (US$ Million) by Application (2020-2031)
Figure 39. Indonesia Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 40. Japan Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 41. South Korea Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 42. Australia Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 43. India Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 44. Indonesia Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 45. Vietnam Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 46. Malaysia Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 47. Philippines Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 48. Singapore Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2031) & (US$ Million)
Figure 49. Central and South America Peptide-Drug Conjugates(PDCs) CDMO Service Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Central and South America Top 5 Players Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (US$ Million) in 2024
Figure 51. Central and South America Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (US$ Million) by Type (2020-2031)
Figure 52. Central and South America Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (US$ Million) by Application (2020-2031)
Figure 53. Brazil Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2025) & (US$ Million)
Figure 54. Argentina Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2025) & (US$ Million)
Figure 55. Middle East and Africa Peptide-Drug Conjugates(PDCs) CDMO Service Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Middle East and Africa Top 5 Players Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (US$ Million) in 2024
Figure 57. South America Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (US$ Million) by Type (2020-2031)
Figure 58. Middle East and Africa Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (US$ Million) by Application (2020-2031)
Figure 59. GCC Countries Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2025) & (US$ Million)
Figure 60. Israel Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2025) & (US$ Million)
Figure 61. Egypt Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2025) & (US$ Million)
Figure 62. South Africa Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (2020-2025) & (US$ Million)
Figure 63. Peptide-Drug Conjugates(PDCs) CDMO Service Industry Chain Mapping
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
